State Street SPDR S&P Biotech ETF (NY:XBI)

156.96 -0.83 (-0.53%)

Delayed Quote Updated: 9:30 AM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

April Is Busting Out For Healthcare And Biotech ↗

April 10, 2023

Last week was a good week for healthcare stocks and most large cap biopharmaceutical stocks resumed an upward trend.

Via Talk Markets

FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits ↗

April 06, 2023

Via Benzinga

Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags ↗

April 03, 2023

It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners.

Via Talk Markets

The Stock Market Rally May Fizzle The Week Of April 3 ↗

April 02, 2023

I think what we’ve seen over the last week or two has been driven by systematic trading and rebalancing of portfolios, as investors have sold financials and moved into mega-cap technology names. But...

Via Talk Markets

Biotech And Life Science Trades: Q1 2023 Performance By The Numbers ↗

April 01, 2023

Despite a strong month and a great finish to the quarter, many traders remain cautious about the market. It’s been a volatile time after the collapse of Silicon Valley Bank, but the first quarter of...

Via Talk Markets

“Don’t Stop Believin'” Stock Market (And Sentiment Results) ↗

March 30, 2023

In this week’s AAII Sentiment Survey result, bullish percent ticked up to 22.5% from 20.9% the previous week.

Via Talk Markets

This Blue Chip Dividend Stock Should Return to Form When the Risk Premium Flips ↗

March 30, 2023

T-bills may be the flavor of the month, but history has shown this top biotech stock is a far better long-term investment.

Via The Motley Fool

The 3 Best Growth Stocks to Buy in the Biotech Sector ↗

March 29, 2023

These three biotech growth stocks are brimming with potential and could offer massive upside for patient investors.

Via InvestorPlace

Can Healthcare Stocks Survive Macro Headwinds? ↗

March 27, 2023

Healthcare stocks are supposed to be defensive plays in a choppy market. However, over the past 18 months, the XLV is flat and down 6% over one year.

Via Talk Markets

Want Diversified Upside in Biotechnology? Check out LABU

March 22, 2023

Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility.

Via MarketBeat

Topics ETFs Stocks

US Judge Weighs Nationwide Ban On Abortion Pills ↗

March 16, 2023

U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is...

Via Benzinga

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

Biotech Stocks And The SVB Collapse — Here's What We Know ↗

March 14, 2023

The collapse of SVB will have a big impact on early-stage, venture-backed companies.

Via Investor's Business Daily

Silicon Valley Bank Meltdown Hits Healthcare Sector As Well ↗

March 13, 2023

The Federal Deposit Insurance Corporation (FDIC) closed Silicon Valley Bank, the banking arm of SVB Financial Group (NASDAQ:

Via Benzinga

Small Cap Biotechs Slammed By SVB Collapse ↗

March 13, 2023

Nothing like a banking crisis to start off a weekend. But maybe by the end of this upcoming week of turmoil we'll worry less about inflation.

Via Talk Markets

6 Stock Market Thoughts For The Week Of March 13 ↗

March 12, 2023

A flight to safety seemed to be at play this week, with the market seeking safety first and asking questions later. This is not unusual, and once the situation is resolved, much of the decline in rates...

Via Talk Markets

Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs ↗

March 10, 2023

New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per...

Via Benzinga

FDA Seeks 10% Increase In Biden's FY 2024 Budget, Proposes Enhancing Regulatory Authorities ↗

March 10, 2023

Via Benzinga

Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading ↗

March 06, 2023

Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD.

Via Talk Markets

FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug' ↗

March 01, 2023

Via Benzinga

When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader? ↗

February 05, 2023

A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?

Via Talk Markets

Stryker, DaVita And These 2 ETFs: CNBC's 'Final Trades' ↗

January 31, 2023

On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named the SPDR S&P Biotech ETF (NYSE: XBI), saying if you "want growth,

Via Benzinga

Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January ↗

January 30, 2023

Biotech stocks are off to a great start in 2023 with the IBB up 4.5% and the XBI up 7.7%.

Via Talk Markets

2 ETFs That Can Set You Up for Life ↗

January 25, 2023

Simplifying your investment strategy can help minimize your risk while still allowing you to earn some great returns.

Via The Motley Fool

Healthcare Sector Is Lagging As We Enter 2022 Earnings Season ↗

January 23, 2023

The healthcare sector is perceived as defensive but in 2023 there is more investor appetite for risk based on the QQQ comeback and the XBI strength.

Via Talk Markets

The Fed Should Stop Right Now ↗

January 19, 2023

A pause to refresh or a mild pullback would be good for the stock market after running hot and heavy. On Wednesday, we saw weaker economic data in retail sales. Unlike previous soft data, the stock...

Via Talk Markets

J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps ↗

January 17, 2023

Large cap biopharmas that outperformed in 2022 were generally weak last week from profit-taking and portfolio rebalancing.

Via Talk Markets

Nice Gains During JPM23 Week: Benign CPI Report Brings Hope For A “Soft Landing” ↗

January 12, 2023

Small-cap speculative biotech stocks regain interest with volatility.

Via Talk Markets

3 Unstoppable ETFs to Stock Up On in 2023 ↗

January 09, 2023

These ETFs could be big winners in the new year.

Via The Motley Fool

ETFs To Buy For 2023 After S&P 500's Worst Year Since 2008 ↗

January 08, 2023

The S&P 500 has dropped 19.4% in 2022. It marked the largest calendar-year decline since a 38% plunge in Lehman Bother’s crisis-laden 2008. Goldman Sachs, Bank of America and JPMorgan predict a U.S....

Via Talk Markets

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.